European Medicines Agency recommends approval of first treatment for pseudobulbar affect

View source ↗

Summary

The EMA recommends approval of the first treatment specifically targeting pseudobulbar affect, signaling a new therapeutic option for this condition.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pseudobulbar Affect